Concepedia

Peiwen Yu

PY

Statistics

Publications

24

Citations

3K

H-Index

22

Active since

2001

Affiliations

Exelixis (United States)(Current)

Mengchao Hepatobiliary Hospital

Fujian Medical University

Fuzhou University

Fujian Institute of Research on the Structure of Matter

Peiwen Yu is an author at Exelixis (United States) specializing in pharmacology, oncology, and medicine.

ORCID

Publications per year

2001–2023

24

Publications

24

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text

, , +17

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

Fawn Qian, Stefan Engst, Peiwen Yu et al. · Cancer Research · 2009 · 338 citations

, , +17

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

Kenneth D. Rice, Naing Aay, Neel K. Anand et al. · ACS Medicinal Chemistry Letters · 2012 · 168 citations · Full text

, , +14

<i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

Frauke Bentzien, Marcus Zuzow, Nathan Heald et al. · Thyroid · 2013 · 130 citations · Full text

, , +16

Discovery of XL413, a potent and selective CDC7 inhibitor

Elena S. Koltun, Amy Lew Tsuhako, David S. Brown et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 92 citations · Full text

, , +9

1–5 of 24